UCSF campus mail box number 0520
Introduction
Malignant gliomas are the most common type of primary malignant brain tumor, with more than 18,000 new cases diagnosed each year in the United States and programmed death 1 (PD-1; pembroluzimab and nivolumab) for metastatic melanoma as well as non-small cell lung cancer (NSCLC) [3] [4] [5] [6] . In regard to cellular immunotherapy, the FDA approved the first vaccine against non-viral cancers (sipuleucel-T) 7 . Furthermore, chimeric antigen receptor (CAR) engineered autologous T cells have induced durable remissions among leukemia patients refractory to conventional therapies including bone marrow transplantation 8, 9 . Extensive preclinical and clinical studies are being conducted to extend these successes to other types of cancer, especially, solid cancer. Cellular immunotherapeutics could be fundamentally classified into vaccine approaches and adoptive transfer of effector cell approaches. In this review, we discuss recent and current efforts in the field of cellular immunotherapy for malignant gliomas.
Cellular vaccine approaches

Tumor cell vaccines
Tumor cell vaccines utilize either autologous or allogeneic tumor cells that are attenuated.
Since the inherent immunogenicity of the tumor cells may be limited, they are often genetically engineered to express costimulatory molecules, cytokines chemokines, or those in combination 10 . Especially, to enhance the presentation of tumor antigens, cytokines that activate antigen-presenting cells (APCs), such as GM-CSF and IL-4 [11] [12] [13] , co-stimulatory molecules, such as CD80 14 have been used.
In preclinical studies, peripheral immunization of rats bearing 9L gliosacroma in the brain with IL-4 transfected 9L cells achieved the most potent therapeutic benefit compared to GM-CSF, IL-12 and IFN-α 15, 16 . IL-4 produced at the local vaccine site appears to promote a T-helper . While the role of CMV in the biology of these tumors is a continued area of study 40 , a recent study of a DC vaccine targeting CMV epitopes in GBM demonstrated promising results, especially in combination with the vaccine-site conditioning with tetanus-toxioid 42 .
A number of clinical trials are conducted in malignant gliomas (Table 1) . DC-based vaccines for brain tumors appear to be safe and can induce anti-tumor immune response. However, objective clinical benefits (objective anti-tumor response and/or extension of survival)
remains to be determined.
Adoptive cell therapy (ACT) of effector cells
In ACT of effector cells, large numbers (typically 1 x 10 6-9 orders) of immune effector cells are (Table 2) . Even though some of these approaches are quite successful in other cancer types, it is important to address unique challenges that arise when these approaches are applied for brain tumors. . Also high-dose IL-2 may lead to capillary leak syndrome, including hypotension, oliguria, pulmonary edema and dyspnea, discouraging further study of the approach. Thus, a randomized phase II or III clinical study was never conducted.
However, owing to recent advances in the field of NK cell biology 46 , there is a renewed interest in NK cell-based immunotherapy for cancer 47 . Recent preclinical advancements of NK cell immunotherapy include augmentation of antibody-dependent cellular cytotoxicity, manipulation of receptor-mediated activation, and adoptive immunotherapy with ex vivo-expanded, CAR-engineered NK cells (reviewed in 48 ).
γδ T cells
In healthy donors, T cells bearing the γδ T cell receptor constitute 0.5-20% of CD3+ T lymphocytes in peripheral blood and in lymphoid tissues . Activating NK cell receptors such as NKG2D and DNAM1 are also present on most γδ T cells, which recognize stress-induced ligands on tumor cells 50, 52 .
Early phase clinical trials have been conducted in non-Hodgkin lymphoma, multiple myeloma, and metastatic solid tumors 53 . In brain tumors, preclinical studies also suggested that γδ . Expanded/activated γδ T-cells from both healthy controls and selected patients have significant cytotoxicity against primary GBM explants
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. Also there are evidence that γδ T cell therapy may be safe for brain tumor patients who undergo standard cytotoxic therapies 56, 57 , opening a previously unexplored approach to cellular immunotherapy of brain tumors.
TIL transfer
TILs are obtained from tumor tissue, draining lymph nodes or malignant effusions. They these cells 63, 64 . Three out of ten patients with recurrent malignant gliomas 63 and four out of ten patients with newly diagnosed malignant gliomas 64 showed radiographic partial response.
However, no study has proven prolongation of the survival of glioma patients. Another study using autologous T-cells transduced with TCR treated 36 patients with metastatic melanoma using high-avidity TCRs that recognized either the MART-1 or gp100 melanoma-melanocyte antigens 67 . Objective cancer regressions were observed in 30% and 19% of patients who received the MART-1 or gp100 TCR, respectively, but severe off-tumor, on-target toxicity was seen in the skin, eyes, and ears due to the presence of melanocytes in and target cell killing 77, 78 . In addition, Abs bind antigens with much greater affinity than do TCRs, resulting in the formation of a more stable immunological synapse 79 . CARs have evolved over the last decade, with progressively increasing co-stimulatory activity. In addition to a single signaling unit derived from the CD3ζ chain or the high-affinity IgG receptor , and EGFRvIII [85] [86] [87] . It should also be noted that CARs can induce toxicity against self-antigens as well. Acute pulmonary toxicity resulting in death was observed after infusion of CAR-T cells specific for ERBB2, likely due to the recognition of low levels of this antigen on pulmonary epithelium 74 . These observations underscore the need for selecting tumor-specific antigens, such as tumor-specific mutation-derived antigens (i.e., neoantigens), for effective and safe ACT. Among these targets, only EGFRvIII is tumor-specific, while others are TAAs. In preclinical animal models, T cells expressing these EGFRvIII-specific
Adoptive transfer of genetically engineered T-cells (CAR
CARs showed potent antitumor activity 85, 86 . 
Conclusion
We discussed recent developments of cellular immunotherapy for malignant brain tumors. environment of brain tumors and develop strategies that are adequate to overcome challenges associated with the environment. In the "Expert Opinion" section below, we will further discuss our perspective.
Expert Opinion
After decades of efforts to revise the longstanding dogma that the brain and tumors arising therein are "immunologically privileged", immunotherapy, including cellular immunotherapy, for brain tumors has been emerging as a promising approach. However, the ultimate success of cellular immunotherapy in brain tumor patients would require advancements in the following areas: 1) feasibility of timely production of cellular therapeutics; 2) paucity and heterogeneity of tumor specific antigens; 3) better strategies to promote antigen-presentation and effector T-cell trafficking; 4) local and systemic immune suppression, and 5) proper interpretation of imaging data for brain tumor patients receiving immunotherapy.
Feasibility of Producing Cellular Therapeutics
Production of autologous cell products inevitably involves lengthy and intensive processes, such as leukapheresis, engineering, expansion, as well as quality-assurance tests and assays. There require substantial costs, infrastructure of the institution as well as invasive procedures for patients, such as leukapheresis. These are important issues to address, especially because we hope that cellular immunotherapy will become effective, standard-of-care therapy in future. Ongoing efforts are directed to development of efficient bioreactors and automated processing systems. Another way to solve the issue is to develop "off-the-shelf" allogeneic cell products that can be safely administered without being rejected by the host immune-system. While this requires multiple immuno-genetic engineering of cells, developments are underway in this direction. . Enhanced CCR2b expression from mesothelin-reactive CAR-T cells and CAR-GD2 T cells led to improved anti-tumor effects against malignant pleural mesothelioma and neuroblastoma 105, 106 . Some of these inventions may be applicable for brain tumors as well.
Local and Systemic Immune Suppression
Brain tumors mediate a variety of immunosuppressive mechanisms to escape from immunological attacks. These include expression of check-point molecules and On the other hand, CAR-T cells also express PD1, and are susceptible to PD1/PDL1 interaction-mediated suppression 113 . It has been shown that blocking PD1
immunosuppression can boost CAR-T cell therapy, likely representing a fruitful area for future study 114, 115 . To address above discussed issues, it is apparent that our ultimate success will largely hinge upon effective collaboration across multiple disciplines. Scientifically, we have to integrate cutting edge progresses in both cancer immunology and central nervous system immunology.
To implement novel combination strategies, it is essential to promote effective collaboration 
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